Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2009

Open Access 01-10-2009 | Original Article

Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer

Authors: Naomi R. Schechter, William D. Erwin, David J. Yang, E. Edmund Kim, Reginald F. Munden, Kenneth Forster, Lina C. Taing, James D. Cox, Homer A. Macapinlac, Donald A. Podoloff

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2009

Login to get access

Abstract

Purpose

To assess the radiation dosimetry and biodistribution of 99mTc-labeled ethylene dicysteine deoxyglucose (99mTc-EC-DG) in patients with non-small-cell lung cancer (NSCLC).

Methods

Serial whole-body scans were acquired 0, 2, 4, 6 and 24 h after injection of 99mTc-EC-DG (925 MBq) in seven NSCLC patients. Radiation dosimetry, blood clearance and SPECT imaging of the primary tumor were assessed.

Results

The critical organ was the bladder wall, with average radiation absorbed dose over all seven patients of 2.47×10−2 mGy/MBq. The average effective dose equivalent and effective dose were 6.20×10−3 mSv/MBq (6.89 mSv/1,110 MBq) and 5.90×10−3 mSv/MBq (6.54 mSv/1,110 MBq), respectively. The primary tumor was visualized with SPECT in six patients. On final pathology, one patient had a granuloma, which did not enhance with 99mTc-EC-DG.

Conclusion

99mTc-EC-DG has acceptable dosimetric and biodistribution properties as a diagnostic tumor-imaging agent. Future studies are planned to evaluate its diagnostic potential.
Literature
1.
Nolop KB, Rhodes CG, Brudin LH. Glucose utilization in vivo by human pulmonary neoplasm. Cancer 1987;60:2682–9.PubMedCrossRef
2.
Patz EFJ, Goodman PC. Positron emission tomography imaging of the thorax. Radiol Clin North Am 1994;32:811–23.PubMed
3.
Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Rad Oncol Biol Phys 1999;44:593–7.PubMedCrossRef
4.
Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, et al. The impact of 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339–50.PubMed
5.
Yoo IeR, Park HJ, Hyun J, Chung YA, Sohn HS, Chung SK, et al. Two cases of pulmonary paragonimiasis on FDG-PET CT imaging. Ann Nucl Med 2006;20:311–5.PubMedCrossRef
6.
Sasaki M, Ichiya K, Kuwabara Y, Otsuka M, Tahara T, Fukumura T, et al. Ringlike uptake of 18F-FDG in a brain abscess: a PET study. J Comput Assist Tomogr 1990;13:829–31.
7.
Gambhir SS, Czernin J, Schwimmer J, Silvermann DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S–93S.PubMed
8.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of F-18 fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972–80.PubMed
9.
Yang DJ, Kim CG, Schechter NR, Azhdarinia A, Yu DF, Oh CS, et al. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 2003;226:465–73.PubMedCrossRef
10.
Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. J Chem 1991;266:4706–12.
11.
Wells L, Gao Y, Mahoney JA, Vosseller K, Chen C, Rosen A, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem 2002;277:1755–61.PubMedCrossRef
12.
Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 1998;273:26277–80.PubMedCrossRef
13.
Black AR, Black JD, Azizkhan-Clifford J. Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143–60.PubMedCrossRef
14.
Yang DJ, Yukihiro M, Yu DF, Ito M, Oh CS, Kohanim S, et al. Assessment of therapeutic tumor response using 99mTc-ethylenedicysteine-glucosamine. Cancer Biother Radiopharm 2004;19:444–58.
15.
Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, Shen S. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 1996;23:525–32.PubMedCrossRef
16.
Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S–61S.PubMed
17.
Erwin WD, Groch MW, Spies SM. Development of a quantitative imaging and MIRD dosimetry software application for radionuclide therapy treatment planning using a fourth generation language (abstract). Radiology 1997;205(Suppl):261.
18.
Erwin WD, Groch MW, Spies SM, Cutrera P, Groch PJ. Clinical validation of a quantitative imaging and MIRD dosimetry software application: retrospective application to anti-B-cell lymphoma MAB studies (abstract). Clin Nucl Med 1998;23:561.CrossRef
19.
Loevinger R, Budinger TF, Watson E; Medical Internal Radiation Dose Committee. MIRD primer for absorbed dose calculations. New York: The Society for Nuclear Medicine; 1991.
20.
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538–46.PubMed
21.
Giraud I, Rapp M, Maurizis JC, Madelmont JC. Application to a cartilage targeting strategy: synthesis and in vivo biodistribution of 14C-labeled quaternary ammonium-glucosamine conjugates. Bioconjug Chem 2000;11:212–8.PubMedCrossRef
22.
International Commission on Radiation Protection. Radiation dose to patients from radiopharmaceuticals, ICRP Publ. No. 53. New York: Pergamon Press; 1988. p. 75–6.
Metadata
Title
Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer
Authors
Naomi R. Schechter
William D. Erwin
David J. Yang
E. Edmund Kim
Reginald F. Munden
Kenneth Forster
Lina C. Taing
James D. Cox
Homer A. Macapinlac
Donald A. Podoloff
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1135-8

Other articles of this Issue 10/2009

European Journal of Nuclear Medicine and Molecular Imaging 10/2009 Go to the issue

Original Article

Quantitative relationship between coronary calcium content and coronary flow reserve as assessed by integrated PET/CT imaging

Image of the Month

Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT

Society Communications

Report on the first EANM young investigators’ meeting (YIM 2009)

Original Article

Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)

Original Article

Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT

Original Article

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer